The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Current and emerging immune therapies in AL amyloidosis: updates on HBI0101 & bispecifics
Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses updates on the treatment of light chain (AL) amyloidosis with immune therapies, including data from a study involving 16 patients treated with HBI0101. Dr Lebel also highlights ongoing research exploring bispecific antibodies in this disease setting, with promising results being demonstrated so far. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this IMS conference, we brought the updated data only on myeloma, but actually our CAR-T study was the first to treat AL amyloidosis patients, which is more, I think, special and less discussed. And we hope to update and to bring the results in the next ASH conference. But we have prospective data on actually 16 amyloidosis patients who were treated thus far in our study. And overall toxicity, even in this very frail population, including also multi-organ involved and mostly cardiac involved patients, safety was quite manageable, again, with no treatment-related deaths...
In this IMS conference, we brought the updated data only on myeloma, but actually our CAR-T study was the first to treat AL amyloidosis patients, which is more, I think, special and less discussed. And we hope to update and to bring the results in the next ASH conference. But we have prospective data on actually 16 amyloidosis patients who were treated thus far in our study. And overall toxicity, even in this very frail population, including also multi-organ involved and mostly cardiac involved patients, safety was quite manageable, again, with no treatment-related deaths. CRS manageable, no ICANS in this population, and the efficacy was very encouraging with 15 of the 16 patients responding. Only one patient did not respond. So we hope to bring this data and even more updated data to the next important conference. In general, immune therapies is maybe the future of AL amyloidosis, similar to myeloma. But this is a rare disease, it’s hard to conduct studies because of it. And cohorts, the patients are more frail. So immune therapies may be a potential challenge in this population. But actually results are encouraging not only with CAR-T, also with bispecifics. There is an interest in this field and there are studies ongoing and results with teclistamab, a bispecific anti-BCMA were already published – not many patients but the responses are good and it’s overall manageable.
Read more...
